Curtain-raiser data keep analysts on edge ahead of Amgen’s big Lumakras/PD-1 combo readout

Will a combination regimen bring Amgen’s big KRAS drug to new heights? That’s the major question Wall Street found itself mulling in the wake of an abstract drop from the annual World Conference on Lung Cancer. While there were some early data available on Amgen’s Lumakras plus a SHP2 inhibitor…

...

Click to view original post